U.S. FDA Grants Regulatory Clearance To IceCure for Next-Gen XSense Cryoablation System With CryoProbes

7/1/24 8:33:23 AM ET

Medical/Dental Instruments

Health Care

Get the next $ICCM alert in real time by email

IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received marketing authorization from the United States Food and Drug Administration (the "FDA") for its next-generation single probe cryoablation system, the XSense™ Cryoablation System with CryoProbes.

Get the next $ICCM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ICCM

Date	Price Target	Rating	Analyst
2/2/2022	$5.65	Buy	Brookline Capital
9/22/2021	$14.50	Buy	Alliance Global Partners

More analyst ratings

$ICCM
Leadership Updates

Live Leadership Updates

IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America
Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systemsImmediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024 CAESAREA, Israel, Aug. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. ("IceCure" or the "Company") (NASDAQ:ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology tha
8/28/23 8:00:00 AM ET
$ICCM
Medical/Dental Instruments
Health Care
IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors
Galit Bar Malik promoted to VP of Operations and Service CAESAREA, Israel, Dec. 6, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the appointment of Vincent Chun Hung Chan to serve as an independent director on the Company's board of directors. Mr. Chan has been a private equity executive for the past three decades, managing and leading more than 80 investment projects supporting company growth via funding and synergistic mergers and acquisitions. Since March 2021, he has been the Director of Samena Capital, a prin
12/6/22 8:00:00 AM ET
$ICCM
Medical/Dental Instruments
Health Care
IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources
CAESAREA, Israel, Nov. 29, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the appointment of Mrs. Merav Nir Dotan to the new position of Vice President, Human Resources. Mrs. Nir Dotan has over two decades of experience in human resources and organizational management. "As the company continues to evolve, we believe investing in our Human Resources function commensurate with an investment in human capital so Mrs. Nir Dotan's appointment is key," stated Eyal Shamir, Chie
11/29/21 1:07:00 PM ET
$ICCM
Medical/Dental Instruments
Health Care

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
CAESAREA, Israel, Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2024 before the Nasdaq Stock Market opens on Tuesday, November 26, 2024. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EST on the same day. Conference call & webcast info: Tuesday, November 26, 2024, at 10:00 am EST US: 1-888-407-2553 Israel/Inte
11/20/24 8:30:00 AM ET
$ICCM
Medical/Dental Instruments
Health Care
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets
Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, Aug. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2024. Significant Near and Short Term Value Enhancing Catalysts U.S. Food and Drug Administration ("FDA") Medical Device Advisory Committee expected
8/20/24 8:30:00 AM ET
$ICCM
Medical/Dental Instruments
Health Care
IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024
CAESAREA, Israel, Aug. 13, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2024 before the Nasdaq Stock Market opens on Tuesday, August 20, 2024. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info: Tuesday, August 20, 2024, at 10:00 am EDTUS: 1-888-407-2553Israel/International: +
8/13/24 8:30:00 AM ET
$ICCM
Medical/Dental Instruments
Health Care

$ICCM
Press Releases

Fastest customizable press release news feed in the world

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
CAESAREA, Israel, Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2024 before the Nasdaq Stock Market opens on Tuesday, November 26, 2024. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EST on the same day. Conference call & webcast info: Tuesday, November 26, 2024, at 10:00 am EST US: 1-888-407-2553 Israel/Inte
11/20/24 8:30:00 AM ET
$ICCM
Medical/Dental Instruments
Health Care
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and breast imaging and pathology specialists PRECICE is exclusively using ProSense® to treat all 233 Luminal A and B patients >50 years of age with early-stage breast cancer, a wider population of patients than ICE3 Article published in European Journal of Cancer Prevention describes the PRECICE study and presents the role of cryoablation in the move toward de-escalation of surgical treatment CAESAREA, Israel, Nov. 19, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medi
11/19/24 8:30:00 AM ET
$ICCM
Medical/Dental Instruments
Health Care
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
FDA decision on marketing authorization expected in the first quarter of 2025 CAESAREA, Israel, Nov. 8, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced the U.S. Food and Drug Administration's ("FDA") Medical Device Advisory Committee Panel's (the "Advisory Panel") favorable recommendation with 9 panelists voting in favor and 5 voting against the benefit-risk profile of IceCure's ProSense®. The majority of panelists voted that the benefits of IceCure's ProSense® System outweigh the risks when us
11/8/24 7:00:00 AM ET
$ICCM
Medical/Dental Instruments
Health Care

U.S. FDA Grants Regulatory Clearance To IceCure for Next-Gen XSense Cryoablation System With CryoProbes

Chat with this insight

Recent Analyst Ratings for
$ICCM

$ICCM
SEC Filings

Amendment: SEC Form F-1/A filed by IceCure Medical Ltd.

SEC Form 6-K filed by IceCure Medical Ltd.

Amendment: SEC Form F-1/A filed by IceCure Medical Ltd.

$ICCM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by IceCure Medical Ltd.

SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

$ICCM
Leadership Updates

Live Leadership Updates

IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources

$ICCM
Market Insights

Live Market Insights

IceCure Medical Presents Key Findings On ProSense Breast Cancer Treatment At Japanese Breast Cancer Society Meeting; Studies Show High Success Rates And Low Recurrence; Terumo Corporation To Seek Regulatory Clearance In Japan By Q1 2025

IceCure Medical Receives Receipt From Nasdaq Minimum Bid Price Notification

IceCure Medical Announces Independent Study Results For ProSense Cryoablation System Published In Peer-Reviewed Journal Cancers

$ICCM
Financials

Live finance-specific insights

$ICCM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024

Brookline Capital initiated coverage on Icecure Medical with a new price target

Alliance Global Partners initiated coverage on Icecure Medical with a new price target

$ICCM
Press Releases

Fastest customizable press release news feed in the world

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

U.S. FDA Grants Regulatory Clearance To IceCure for Next-Gen XSense Cryoablation System With CryoProbes

Chat with this insight

Recent Analyst Ratings for $ICCM

$ICCM SEC Filings

Amendment: SEC Form F-1/A filed by IceCure Medical Ltd.

SEC Form 6-K filed by IceCure Medical Ltd.

Amendment: SEC Form F-1/A filed by IceCure Medical Ltd.

$ICCM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by IceCure Medical Ltd.

SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

$ICCM Leadership Updates

Live Leadership Updates

IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources

$ICCM Market Insights

Live Market Insights

IceCure Medical Presents Key Findings On ProSense Breast Cancer Treatment At Japanese Breast Cancer Society Meeting; Studies Show High Success Rates And Low Recurrence; Terumo Corporation To Seek Regulatory Clearance In Japan By Q1 2025

IceCure Medical Receives Receipt From Nasdaq Minimum Bid Price Notification

IceCure Medical Announces Independent Study Results For ProSense Cryoablation System Published In Peer-Reviewed Journal *Cancers*

$ICCM Financials

Live finance-specific insights

$ICCM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024

Brookline Capital initiated coverage on Icecure Medical with a new price target

Alliance Global Partners initiated coverage on Icecure Medical with a new price target

$ICCM Press Releases

Fastest customizable press release news feed in the world

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

Recent Analyst Ratings for
$ICCM

$ICCM
SEC Filings

$ICCM
Large Ownership Changes

$ICCM
Leadership Updates

$ICCM
Market Insights

IceCure Medical Announces Independent Study Results For ProSense Cryoablation System Published In Peer-Reviewed Journal Cancers

$ICCM
Financials

$ICCM
Analyst Ratings

$ICCM
Press Releases